NeOnc Technologies Reports No Revenue and Increased Losses in Latest Financial Filing

NeOnc Technologies Holdings, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded no revenue for the three months ended June 30, 2025, a decrease from $20,000 in the same period last year. For the six months, revenue fell to $39,990 from $63,000 year-over-year. The company’s operating expenses surged to $5.7 million for the quarter, compared to $1.3 million in the prior year, driven primarily by increased research and development costs, legal and professional fees, and substantial share-based compensation expenses totaling $3.5 million.

The financial performance reflects a net loss of $5.7 million for the quarter, compared to a loss of $4.5 million in the same quarter of 2024. For the six-month period, the net loss escalated to $38 million, significantly higher than the $7.5 million loss reported in the previous year. The accumulated deficit reached $88.6 million as of June 30, 2025, indicating ongoing financial strain. The company’s cash position improved slightly, with cash and cash equivalents totaling $125,039, up from $64,893 at the end of the previous fiscal year.

Strategically, NeOnc has been active in expanding its operations and product pipeline. The company is advancing its lead product candidate, NEO100, which is currently in clinical trials for glioblastoma. Additionally, NeOnc has initiated a second product candidate, NEO212, which has received FDA acceptance for its investigational new drug application. The company has also entered into a binding letter of intent for a potential acquisition of JandB Holdings LLC, which is expected to enhance its growth strategy.

Operationally, NeOnc has seen an increase in research and development activities, with expenses rising due to the addition of clinical trial sites and recruitment efforts for its product candidates. The company has also expanded its advisory services, incurring an advisory fee of $11.7 million related to its recent public listing on NASDAQ. However, the company faces substantial liquidity challenges, as it does not have sufficient capital to fund operations for the next twelve months without additional financing.

Looking ahead, NeOnc acknowledges the need for substantial additional funding to support its ongoing operations and product development. The company plans to finance its activities through a combination of public or private equity offerings and debt financing. However, there is uncertainty regarding the availability of such financing on favorable terms. The company’s ability to continue as a going concern is contingent upon its success in raising additional capital and achieving operational milestones.